These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26612518)

  • 1. Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance.
    Capetti A; Cossu MV; Rizzardini G
    Expert Opin Pharmacother; 2015; 16(17):2689-702. PubMed ID: 26612518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Darunavir/cobicistat once daily for the treatment of HIV.
    Kakuda TN; Crauwels H; Opsomer M; Tomaka F; van de Casteele T; Vanveggel S; Iterbeke K; de Smedt G
    Expert Rev Anti Infect Ther; 2015 Jun; 13(6):691-704. PubMed ID: 25962100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat.
    Curran A; Pérez-Valero I; Moltó J
    AIDS Rev; 2015; 17(2):114-20. PubMed ID: 26035169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
    Negredo E; Clotet B
    Expert Opin Pharmacother; 2018 Jun; 19(8):929-934. PubMed ID: 29767543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.
    Bartels H; Decosterd L; Battegay M; Marzolini C
    J Antimicrob Chemother; 2017 Sep; 72(9):2574-2577. PubMed ID: 28575323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
    Deeks ED
    Drugs; 2014 Feb; 74(2):195-206. PubMed ID: 24343782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS.
    Putcharoen O; Do T; Avihingsanon A; Ruxrungtham K
    Drug Des Devel Ther; 2015; 9():5763-9. PubMed ID: 26566368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cobicistat : a new opportunity in the treatment of HIV disease?
    Capetti A; Rizzardini G
    Expert Opin Pharmacother; 2014 Jun; 15(9):1289-98. PubMed ID: 24819446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological aspects of darunavir/cobicistat].
    González-Domenech CM; Palacios R; Santos J
    Enferm Infecc Microbiol Clin; 2016 May; 34 Suppl 1():30-33. PubMed ID: 28081761
    [No Abstract]   [Full Text] [Related]  

  • 10. Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran.
    Kakadiya PP; Higginson RT; Fulco PP
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133562
    [No Abstract]   [Full Text] [Related]  

  • 11. Atazanavir sulfate + cobicistat for the treatment of HIV infection.
    Antunes F
    Expert Rev Anti Infect Ther; 2017 Jun; 15(6):569-576. PubMed ID: 28443391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection.
    Sherman EM; Worley MV; Unger NR; Gauthier TP; Schafer JJ
    Clin Ther; 2015 Sep; 37(9):1876-93. PubMed ID: 26319088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.
    Kakuda TN; Brochot A; Tomaka FL; Vangeneugden T; Van De Casteele T; Hoetelmans RM
    J Antimicrob Chemother; 2014 Oct; 69(10):2591-605. PubMed ID: 24951533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations.
    Stillemans G; Belkhir L; Vandercam B; Vincent A; Haufroid V; Elens L
    Clin Pharmacokinet; 2021 Feb; 60(2):177-189. PubMed ID: 32696441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Darunavir/cobicistat monotherapy. Experience in a tertiary hospital].
    Yunquera-Romero L; Asensi-Díez R; Del Rio-Valencia JC; Muñoz-Castillo I; Castaño-Carracedo MA
    Rev Esp Quimioter; 2016 Dec; 29(6):308-317. PubMed ID: 27888600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simplification of ART in a patient living with multidrug resistant HIV-1: A case report using twice daily cobicistat and darunavir.
    Brizzi MB; Novak RM; Chiampas TD
    Int J STD AIDS; 2019 Nov; 30(13):1333-1336. PubMed ID: 31631777
    [No Abstract]   [Full Text] [Related]  

  • 17. Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial.
    Brown K; Patterson-Browning B; Liu C; Patel M; Stewart L; Nettles RE
    Rev Recent Clin Trials; 2017; 12(3):174-181. PubMed ID: 28403798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darunavir for the treatment of HIV infection.
    Spagnuolo V; Castagna A; Lazzarin A
    Expert Opin Pharmacother; 2018 Jul; 19(10):1149-1163. PubMed ID: 29913082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS.
    Navarro J; Curran A
    HIV AIDS (Auckl); 2016; 8():175-182. PubMed ID: 27843352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat
    Roberts O; Khoo S; Owen A; Siccardi M
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.